GO
Loading...

Pharmaceuticals

More

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...

  • Sandoz loses bid to shield psoriasis drug Friday, 5 Dec 2014 | 2:09 PM ET

    Dec 5- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits. Taranto only ruled that the lawsuit against Amgen was premature because Sandoz had not yet sought approval for the drug from the U.S. Food and Drug...

  • Biotech stocks to watch at ASH  Friday, 5 Dec 2014 | 6:45 AM ET

    The American Society of Hematology is holding a massive conference in San Francisco on Saturday. CNBC's Meg Tirrell tells why pharma and biotech investors are paying close attention.

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...

  • Lawsuit claims 'kickback' scheme at Sanofi Wednesday, 3 Dec 2014 | 3:27 PM ET
    Ousted Sanofi CEO Christopher Viehbacher

    A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.

  • Many posts going at North Carolina research site. LONDON, Dec 3- GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina...

  • UPDATE 1-ADMA's immune deficiency drug meets main goal Wednesday, 3 Dec 2014 | 12:59 PM ET

    Dec 3- Drugmaker ADMA Biologics Inc said its drug to treat immune deficiency met the main goal in a late-stage study, sending its shares on a roller-coaster ride. The company's shares rose as much as 17.5 percent to a record high of $14.00 before selling set in. PIDD, which affects about 500,000 people in the United States, weakens the immune system, allowing...

  • ADMA's immune deficiency drug meets main goal Wednesday, 3 Dec 2014 | 8:36 AM ET

    Dec 3- Drugmaker ADMA Biologics Inc said its drug to treat immune deficiency was found to be effective in a late-stage study. The drug, RI-002, met the main goal of preventing serious bacterial infections in patients with primary immune deficiency disease. Trading in the company's shares were halted ahead of the announcement and had not resumed as of 08:34 a.m....

  • *Otsuka Holdings dives to more than 1- month low after M&A news. TOKYO, Dec 3- Japan's Nikkei share average rose to a more than seven-year high on Wednesday after Wall Street gained and the dollar hit a fresh seven-year high against the yen, but Otsuka Holdings tumbled on news that it will buy a U.S. drugmaker for about $3.5 billion. "It is possible that the market may...

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • AstraZeneca on failed Pfizer deal  Friday, 28 Nov 2014 | 4:35 AM ET

    The tax inversion announcement seriously reduced the likelihood of the Pfizer AstraZeneca deal going ahead says CNBC's Catherine Boyle.

  • Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.

  • I'm a strong believer in Europe: Astrazeneca CEO  Friday, 28 Nov 2014 | 2:45 AM ET

    Discussing a possible British exit from the European Union, Pascal Soriot, CEO of Astrazeneca, says he is a believer in Europe and immigration is key to getting the best talent for his company.

  • Astrazeneca could eye tech firms for M&A: Expert  Friday, 28 Nov 2014 | 2:30 AM ET

    Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.

  • Pfizer deal would have failed: Astrazeneca CEO  Friday, 28 Nov 2014 | 1:05 AM ET

    Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • Pfizer to join forces with AstraZeneca?  Wednesday, 26 Nov 2014 | 4:35 AM ET

    American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".

  • Pfizer to renew pursuit of AstraZeneca?  Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Searching for relief from expensive generic drugs Tuesday, 25 Nov 2014 | 2:24 PM ET
    Senator Amy Klobuchar

    Generic drug costs have risen so much that some drugs have surpassed their equivalents in other developed countries, the New York Times reports.